🇺🇸 FDA
Pipeline program

Laquinimod 0.6

LAQ-MS-201

Phase 2 small_molecule terminated

Quick answer

Laquinimod 0.6 for Relapsing Multiple Sclerosis is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Relapsing Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials